BibTex format
@article{Larrouy-Maumus:2023:10.1007/s10096-023-04587-9,
author = {Larrouy-Maumus, G and Dortet, L and Nix, ID and Maier, T and Oberheitmann, B and Sparbier, K and Kostrzewa, M},
doi = {10.1007/s10096-023-04587-9},
journal = {European Journal of Clinical Microbiology and Infectious Diseases: an international journal on pathogenesis, diagnosis, epidemiology, therapy, and prevention of infectious diseases},
pages = {669--679},
title = {Two-site study on performances of a commercially available MALDI-TOF MS-based assay for the detection of colistin resistance in Escherichia coli},
url = {http://dx.doi.org/10.1007/s10096-023-04587-9},
volume = {42},
year = {2023}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Colistin is a last resort drug for the treatment of multiple drug-resistant (MDR) Gram-negative bacterial infections. Rapid methods to detect resistance are highly desirable. Here, we evaluated the performance of a commercially available MALDI-TOF MS-based assay for colistin resistance testing in Escherichia coli at two different sites. Ninety clinical E. coli isolates were provided by France and tested in Germany and UK using a MALDI-TOF MS-based colistin resistance assay. Lipid A molecules of the bacterial cell membrane were extracted using the MBT Lipid Xtract Kit™ (RUO; Bruker Daltonics, Germany). Spectra acquisition and evaluation were performed by the MBT HT LipidART Module of MBT Compass HT (RUO; Bruker Daltonics) on a MALDI Biotyper® sirius system (Bruker Daltonics) in negative ion mode. Phenotypic colistin resistance was determined by broth microdilution (MICRONAUT MIC-Strip Colistin, Bruker Daltonics) and used as a reference. Comparing the results of the MALDI-TOF MS-based colistin resistance assay with the data of the phenotypic reference method for the UK, sensitivity and specificity for the detection of colistin resistance were 97.1% (33/34) and 96.4% (53/55), respectively. Germany showed 97.1% (33/34) sensitivity and 100% (55/55) specificity for the detection of colistin resistance by MALDI-TOF MS. Applying the MBT Lipid Xtract™ Kit in combination with MALDI-TOF MS and dedicated software showed excellent performances for E. coli. Analytical and clinical validation studies must be performed to demonstrate the performance of the method as a diagnostic tool.
AU - Larrouy-Maumus,G
AU - Dortet,L
AU - Nix,ID
AU - Maier,T
AU - Oberheitmann,B
AU - Sparbier,K
AU - Kostrzewa,M
DO - 10.1007/s10096-023-04587-9
EP - 679
PY - 2023///
SN - 0934-9723
SP - 669
TI - Two-site study on performances of a commercially available MALDI-TOF MS-based assay for the detection of colistin resistance in Escherichia coli
T2 - European Journal of Clinical Microbiology and Infectious Diseases: an international journal on pathogenesis, diagnosis, epidemiology, therapy, and prevention of infectious diseases
UR - http://dx.doi.org/10.1007/s10096-023-04587-9
UR - https://www.ncbi.nlm.nih.gov/pubmed/36973378
UR - https://link.springer.com/article/10.1007/s10096-023-04587-9
VL - 42
ER -